The present analysis confirmed and for the first time validated the capacity of EASIX-pre to predict the risk of CRS/ICANS in two additional cohorts treated with axi-cel and a variety of CD19-directed CAR-T cell products. This evidence concerns the gene CD19 and congenital rubella syndrome.